Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 12:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 778 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gram Positive Bacterial Infection Clear all
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of SQ109 on QTc Interval in Healthy Subjects

NCT01874314
View directory record Official record
Conditions
Tuberculosis
Interventions
SQ109, SQ109 Placebo, Moxifloxacin
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 25, 2026, 12:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Quality by Maintaining Accurate Problems in the EHR

NCT02596087
View directory record Official record
Conditions
Asthma, Atrial Fibrillation, Chronic Obstructive Pulmonary Disease, Coronary Artery Disease, Congestive Heart Failure, Hyperlipidemia, Hypertension, Myocardial Infarction, Sickle Cell Disease, Sleep Apnea, Smoking, Stroke, Tuberculosis
Interventions
Problem List Suggestion
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Portland, Oregon • Camp Hill, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 25, 2026, 12:19 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Ph1 Study of Valortim and Doxycycline in Humans

NCT00964834
View directory record Official record
Conditions
Anthrax
Interventions
Doxycycline and Valortim, Placebo Antibiotic and Valortim, Placebo Antibiotic and Placebo Valortim
Drug
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2010 · Synced Oct 25, 2026, 12:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®

NCT06112834
View directory record Official record
Conditions
Botulism
Interventions
rBV A/B
Biological
Lead sponsor
California Department of Public Health
Other
Eligibility
18 Years to 69 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Richmond, California • West Jefferson, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 25, 2026, 12:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

NCT01571414
View directory record Official record
Conditions
Tuberculosis
Interventions
PA-824, Efavirenz (EFV), Lopinavir/Ritonavir (LPV/r), Rifampin (RIF)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
San Francisco, California • Baltimore, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 25, 2026, 12:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

High and Low Resource Interventions to Promote HPV Vaccines

NCT03824093
View directory record Official record
Conditions
Human Papilloma Virus, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Meningitis, Meningococcal, Communication, Satisfaction
Interventions
AFIX Only, AFIX+ Provider Communication Training
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 25, 2026, 12:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-1607 SAD Study in Healthy Subjects

NCT01791049
View directory record Official record
Conditions
Serious Infections Due to Known or Suspected Gram-positive Pathogens
Interventions
TD-1607, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 25, 2026, 12:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization

NCT03455309
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
NDV-3A, Placebo
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
17 Years to 35 Years · Male only
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fort Benning, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 25, 2026, 12:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

NCT02096263
View directory record Official record
Conditions
Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions
Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 25, 2026, 12:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS

NCT04071158
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
RSV Vaccine, Tdap, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
713 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
16
States / cities
Stockbridge, Georgia • Honolulu, Hawaii • Wichita, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 25, 2026, 12:19 PM EDT
Completed Phase 2 Interventional

TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis

NCT00023426
View directory record Official record
Conditions
Tuberculosis
Interventions
rifapentine
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2005 · Synced Oct 25, 2026, 12:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers

NCT01162486
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
Rifampin & midazolam, rifapentine and midazolam
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 25, 2026, 12:19 PM EDT
Recruiting Not applicable Interventional

Economic Incentives and vDOT for Latent Tuberculosis Infection

NCT05022862
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Usual Care, Video Directly Observed Therapy alone, Video Directly Observed Therapy plus Financial Incentives
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 25, 2026, 12:19 PM EDT
Recruiting Phase 3 Interventional

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452
View directory record Official record
Conditions
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
Interventions
VE303, Placebo
Biological
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 12:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Rhode Island's Tuberculosis Preventive Services in Primary Care

NCT04188041
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
TB Infection ECHO
Other
Lead sponsor
Kent Hospital, Rhode Island
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pawtucket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 25, 2026, 12:19 PM EDT
Completed Phase 1 Interventional

Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients

NCT01690403
View directory record Official record
Conditions
Tuberculosis
Interventions
rifapentine (M000473), EFZ EMT TDF
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2015 · Synced Oct 25, 2026, 12:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD)

NCT03548051
View directory record Official record
Conditions
Clostridial Infection, Dysbiosis, Probiotic Therapy
Interventions
Fecal Microbiota Transplantation (FMT), Saline
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Decatur, Georgia • Durham, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 25, 2026, 12:19 PM EDT
Completed No phase listed Observational

Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance

NCT02534727
View directory record Official record
Conditions
Tuberculosis, Non-Tuberculosis Mycobacteria
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 25, 2026, 12:19 PM EDT
Completed Not applicable Interventional

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

NCT00013871
View directory record Official record
Conditions
HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
38
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 25, 2026, 12:19 PM EDT
Completed Phase 2 Interventional

A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections

NCT00021567
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection
Interventions
Interferon Gamma for Aerosol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 12:19 PM EDT
Completed No phase listed Observational

Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults

NCT05283967
View directory record Official record
Conditions
Tuberculosis
Interventions
urine colorimetric assay
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
4 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Newark, New Jersey • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 25, 2026, 12:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule

NCT01641991
View directory record Official record
Conditions
Bacillus Anthracis (Anthrax)
Interventions
BioThrax®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Atlanta, Georgia • Cincinnati, Ohio • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 25, 2026, 12:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Promoting Adherence to Treatment for Latent TB Infection Through Text Messaging

NCT02690818
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Regularly scheduled LTBI medication reminder text messages
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 25, 2026, 12:19 PM EDT
Completed Not applicable Interventional

A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease

NCT00002058
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clofazimine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 12:19 PM EDT